BOSTON SCIENTIFIC CORP (BSX)
BOSTON SCIENTIFIC CORP (BSX) from its SEC filings: 2025 revenue $20.1 billion (+20% vs the year before), free cash flow $3.7 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $20.1 billion |
| Revenue growth | +20% |
| Free cash flow | $3.7 billion |
| Diluted EPS | $1.94 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +8% |
| Cash | $539.0 million |
| Long-term debt | $4.8 billion |
| Share count, 1 year | -2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-25. Education only, not financial advice.